Add Yahoo as a preferred source to see more of our stories on Google. NEW BERN, N.C. (WNCT) — The Urology team at CarolinaEast Health System announced they are offering A quablation therapy and have ...

The FDA has approved tadalafil (Cialis) for the once daily use as a treatment for benign prostatic hyperplasia (BPH). The agency also approved the medication for once daily use as a treatment for men ...

Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA) has ...

Therapeutic Dr Allen’s Devices are designed to treat different chronic health conditions, including kidney stones (known as ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this ...

BPH is a natural enlargement of the prostate. 50 percent of men in their 50′s will have this condition, along with 80 percent of men in their 80′s. Frequent need to use the bathroom is a common side ...

Add Yahoo as a preferred source to see more of our stories on Google. Men aged 50 and above are most commonly affected. (Getty Images) (Rafael Ben-Ari via Getty Images) This common condition affects ...